Home › Ziarco Pharma Ltd - Phase 2a Psoriasis Study Initiated With Ziarco's Lead Compound ZPL-389
 

Keywords :   


Ziarco Pharma Ltd - Phase 2a Psoriasis Study Initiated With Ziarco's Lead Compound ZPL-389

2016-02-03 02:06:37| drugdiscoveryonline Home Page

Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs against inflammatory skin disorders, recently announced that dosing has started in a Phase 2a proof of concept study in moderate to severe psoriasis with ZPL-389

Tags: study lead phase initiated

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
19.05 Dr. Squatch Launches Bronco Bricc
19.05Gillette Venus Announces Ambassadors Ahead of the Olympic and Paralympic Games Paris 2024
19.05Eastern North Pacific Tropical Weather Outlook
More »